New liquid biopsy workflow using CTC enrichment followed by targeted 56-gene NGS panel for somatic variant detection

Liquid biopsies represent a major breakthrough in the ability to detect molecular changes in tumor progression without the need for a tissue biopsy. They offer the potential to characterize cancer in real time using only a routine blood draw, enabling targeted therapies to be used simultaneously monitoring for response and resistance. Until recently, this approach has been limited by the available amount of tumor DNA that can be recovered from peripheral blood samples. The IsoFlux System enriches rare tumor cells circulating in the blood using a combination of epithelial and mesenchymal markers, and delivers them at high purity for molecular analysis. Swift’s Accel-Amplicon 56G Oncology Panel provides sensitive mutation detection across 56 cancer-related genes using very low starting DNA inputs from the IsoFlux System, making this combination of technologies especially appropriate for liquid biopsy samples.

 

The combined workflow begins with a standard blood draw and proceeds to CTC enrichment using epithelial and mesenchymal antibodies. The captured CTCs undergo DNA extraction and purification without the need for whole genome amplification. The genomic DNA then goes through target enrichment using the 56G Oncology Panel and library preparation for Illumina sequencers. The resulting data utilizes a custom bioinformatics pipeline designed to identify low frequency variants from liquid biopsy samples. The complete workflow is described in an application note and the products involved are available from Fluxion and Swift. For more information, please visit: www.fluxionbio.com and www.swiftbiosci.com

Download the application note